Hospital & Unit Operations

This record covers BD's medication dispensing estate as sold to hospital pharmacy: the BD Pyxis family of automated dispensing systems and the BD HealthSight analytics layer that runs on top of it. Becton Dickinson as a whole is far too broad to grade on these axes, spanning syringes, catheters, surgical instrumentation and much else, so the parent is noted here rather than indexed. BD's own securities filings draw the same boundary this record does, separating the Dispensing quality management system from the Infusion quality management system that governs BD Alaris. Alaris sits outside this record. The hardware is the Pyxis ES portfolio: MedStation ES dispensing cabinets with CUBIE pocket technology, Anesthesia Station ES for the operating room, MedBank countertop and restricted access stations for controlled substances and temperature sensitive stock, supply dispensing cabinets, and Med Link Queue and Waste for witnessed disposal. It reached BD through the $12 billion CareFusion acquisition in 2015 and is still manufactured by CareFusion 303, Inc. in San Diego. The intelligence sits in BD HealthSight. Diversion Management is the substantive machine learning product. It draws on dispensing behaviour and the electronic medical record, compares an individual clinician against a dynamically selected peer group within the facility, produces an individual risk score, and names the behaviours that contributed to it, including overrides, cancelled transactions, and delays in dispensing, administering and wasting medication. It automates controlled substance reconciliation, flags discrepancies, and routes cases into an investigation workflow with assignment to named investigators. Inventory Optimization and the HealthSight Viewer complete the layer. Two things make this record unusual and both belong in front of a buyer. The mechanism description is more specific than anything else in this lane, naming the signals and the comparison population rather than stopping at the phrase predictive analytics. And the regulatory and security record is documented in extraordinary detail, because securities law and coordinated vulnerability disclosure compelled it. A November 2024 FDA Warning Letter cites the dispensing quality system, and BD carried a $68 million liability for the response as of March 2026. Five cybersecurity advisories reached the Cybersecurity and Infrastructure Security Agency between 2018 and 2022. None of that is concealed, and a buyer here has more primary source material to work with than for any comparable product. What that material says is a separate question from how completely it is available, and the grades below keep the two apart.

Omnicell sells the physical infrastructure of hospital medication management and has spent the past six years attaching an intelligence layer to it. The hardware came first and still carries the business: XT automated dispensing cabinets at the point of care, XR2 robotics in the central pharmacy, IV compounding systems, and supply cabinets, sold into acute hospitals, health systems, retail and specialty pharmacies, long term care and residential settings, in the United States and internationally. The software sits on top of that installed base. OmniCenter is the established on premise platform. OmniSphere, introduced at the end of 2024, is the cloud native workflow engine and data platform intended to succeed it, running on Amazon Web Services and sold on enterprise wide visibility and interoperability with the electronic health record. Omnicell One, generally available since August 2020, is the predictive layer over pharmacy inventory. Omnicell Analytics targets drug diversion. Titan XT is the next generation cabinet, which the company reported in April 2026 was entering health system capital planning cycles. In October 2025 Omnicell acquired ANiGENT, a St. Louis software company whose MAAP Analytics platform does machine learning driven drug diversion detection and originated at Mayo Clinic. ANiGENT continues to trade under its own name with its own site and product, so it is indexed separately in this category rather than folded in here. Anyone assessing Omnicell's position in diversion surveillance should read both records together, and should note that Omnicell's HITRUST certification scope enumerates specific Omnicell products and does not name MAAP Analytics. The company frames all of this as the Autonomous Pharmacy, and its own securities filing describes the business as empowering autonomous medication management. Read closely, the same passage commits to equipping pharmacists and nurses to focus on patient care rather than administrative tasks, which is a narrower claim than the brand implies and a more accurate one. The autonomy on offer is the removal of counting, stocking and reconciling, not of clinical judgement. Omnicell is a public company, founded in 1992, headquartered in Fort Worth, Texas and listed on Nasdaq as OMCL, with an engineering innovation lab opened in Austin in 2025. Its scale is documented in filings rather than asserted in marketing, which is unusual in this index and matters for how the grades below should be read. The low AI centrality grade describes what the models built inside this business do. It is not a judgement on the size, maturity or quality of the business itself, which is among the largest in the category.

Forescout Medical Device Security is indexed as a product rather than as a company, following the ruling applied to Vscan Air and Optum Integrity One. Forescout is a general enterprise security business serving government, financial services and industrial operators alongside healthcare, and it would fail the horizontal filter as a whole. The healthcare product has its own lineage and is assessed on its own terms. That lineage matters. The product was CyberMDX, a healthcare specific medical device security company acquired by Forescout in 2022, and its material still identifies itself as formerly the CyberMDX Healthcare Security Suite. So this is a dedicated healthcare product absorbed into a horizontal platform rather than a vertical bolted onto one, which is the distinction the horizontal filter is meant to catch. The function is asset intelligence and risk on the clinical network. Agentless discovery finds every connected medical device, including devices behind firewalls and serial gateways that ordinary scanning misses, classifies them automatically into a taxonomy, and assesses each one on known exposures, attack potential and operational criticality. Detection is described in the company's own words as artificial intelligence and rule based, which is an unusually honest construction. Enforcement follows visibility, with per device access policy, smart isolation restricting a device to authorised nodes, and segmentation policies designed from observed communication patterns. Two capabilities distinguish this from general network security and both are healthcare specific. FDA device class and recall status are tracked alongside cyber risk, so a biomedical engineering team sees regulatory and security exposure together. And manufacturer disclosure statement integration brings the standardised medical device security form into the platform, which is the document a hospital technology management team actually works from. A third capability sits outside security entirely. Utilisation dashboards let hospitals monitor device performance, identify anomalies and move equipment between departments, which is a biomedical operations tool built on the same telemetry. Evidence includes Vedere Labs research analysing more than two million devices across 45 healthcare delivery organisations and publishing 162 vulnerabilities in connected medical devices, participation in the KLAS Healthcare IoT Security 2026 report with customers interviewed, and inclusion in the 2025 Gartner market guide for medical device risk management platforms. One thing a reader should weigh, and it is the sharpest finding on this record. The product's naming and its artificial intelligence claim are both unstable. The same marketing sentence appears on Forescout pages describing the platform as combining discovery techniques with AI powered intelligence in one version and with cloud powered intelligence in another, and the product is variously presented as Medical Device Security, part of Forescout Continuum, part of the Forescout 4D Platform and as the Forescout Vistaro platform. A buyer should establish which product they are being sold and what the intelligence in it actually is.

Current Health enables hospital at home. Its platform combines a continuous vital signs wearable with aggregated data from other remote monitoring devices and patient reported information, presenting a picture of a patient's trajectory to a clinical team that is not in the room. Around that sits the operational machinery that makes acute care at home actually work: device kits, in home installation, patient onboarding, virtual visits and care coordination. Oncology at home is addressed as a distinct programme alongside general acute and chronic care. The wearable received United States Class II clearance in February 2019 as an artificial intelligence powered device, monitoring vital signs continuously and delivering patient specific alerts, with further machine learning related clearance reported in 2021. The company was founded in 2014 in Edinburgh by Christopher McGhee after watching his grandmother manage chronic obstructive pulmonary disease, dementia and congestive heart failure at home, and is now headquartered in Boston. Deployment reach is the strongest fact on this record. The company states that more than one third of all patients in the United States who have had a hospital at home experience were cared for through its platform, with more than 70,000 patients across care models. Named health system partners include Mass General Brigham, Geisinger, UC Davis, Atrium Health, Baptist Health, UMass Memorial Health, Virtua Health and OSF HealthCare. A partnership with Cardinal Health's Velocare handles last mile fulfilment, installation and retrieval of in home monitoring kits. Ownership has moved twice and a reader should understand both moves. Best Buy acquired the company in October 2021 for 400 million dollars and sold it back to founder Christopher McGhee in June 2025, exiting care at home entirely and recording 109 million dollars of restructuring charges followed by a further 192 million dollar impairment as it wound down remaining health system relationships. The company is independent again under its original founder. The reason for that exit is the most important commercial fact in this record and it is not about the technology. Acute hospital at home in the United States is paid for through a federal waiver whose renewal has repeatedly been caught in budget negotiations, and that uncertainty was cited directly by the acquirer as why adoption scaled more slowly than expected. Roughly 400 hospitals across 142 systems in 30 states were approved under the waiver as of mid 2025, against 20 programmes before it existed. Any buyer evaluating this category is underwriting a reimbursement policy as much as a product. Two dedicated passes located no pricing, no security attestation, no data handling statement and no peer reviewed outcome study.

BioIntelliSense replaces the four hourly vital signs check with a coin sized sensor worn on the upper left chest. The BioButton captures heart rate, respiratory rate, skin temperature, body position and activity continuously, generating thousands of measurements per patient per day, which flow through BioHub wireless gateways to BioCloud analytics and surface in the BioDashboard clinical intelligence system. Two device variants exist: a single patient disposable and a rechargeable multi patient version for inpatient use, the latter cleared alongside the dashboard in October 2024. An earlier acquisition brought in a separately cleared clinical intelligence platform. The design decision that defines the product is exception management. Rather than streaming waveforms to a central station, the system holds personalised trending thresholds per patient and notifies only on deviation, which is what allows one clinician to watch hundreds of patients at once. The company publishes the two numbers that make that claim assessable: fewer than one notification per patient per day, and clinician engagement with those notifications at 99.71 percent. Alert fatigue is the recognised failure mode of continuous monitoring, and publishing both the volume and the response rate is the pair of figures that shows alerts are being acted on rather than dismissed. Evidence is genuine and includes an outcome study. Peer reviewed research in the Journal of Clinical Medicine covered nearly 12,000 hospitalised patients across the medical surgical units of two hospitals over 15 months, reporting reduced length of stay, low alert notification rates and earlier intervention on deterioration events. Separately, an independent academic validation published on the device's activity and position detection in children reported sensitivity and specificity figures the company did not commission, including results that are candidly mixed. More than 400,000 patients had been monitored as of October 2025. Deployment includes a full system reference rather than a pilot. Houston Methodist completed expansion across all 2,653 non intensive care beds at its eight hospitals, with a centralised command centre staffed by a multidisciplinary team. Intermountain Health and TriHealth are also named. The commercial argument is built on the alternative rather than on the product, and is unusually well sourced: continuous telemetry costs hospitals up to 1,400 dollars per patient per day, one review found 22.3 percent of patients inappropriately assigned to telemetry at admission with over half monitored longer than guidelines recommend, and a 2024 multicentre study attributed 33 percent of patient sleep interruptions to routine vital sign checks. Based in Denver. Two dedicated passes located no pricing of any kind, no security attestation, no trust centre and no data handling statement.

Aidin runs the discharge referral, from the moment a case manager decides a patient needs post acute care to the moment a facility accepts them. Referrals, records, authorizations and care partner relationships sit in one platform, and the document layer absorbs the formats this work still arrives in, pulling material from fax, email and the company's own print path and classifying it against the right patient and request. Task flags surface incomplete flows, at risk cases and overdue assignments, and a secure messaging layer replaces the phone calls. The distinctive design choice is the open market. Rather than routing patients to a hospital's existing preferred partners, Aidin presents post acute providers with objective quality, satisfaction and outcome data so the patient can choose, and it operates a national directory of care partners on the other side. Post acute providers get free access to receive referrals, with paid tiers named as Verified, Community and Enterprise unlocking record system integration, custom reporting and team workflow. That two sided structure means the platform's reach on the receiving side is a commercial asset in its own right. Customers named in company case material include UCLA Health, five hospitals of the Ohio State University Medical Center, St. Luke's, Elmhurst Edward Hospital and Western Maryland Health System, with stated objectives around average length of stay, inpatient bed capacity and readmission reduction. Regulatory posture is more directly addressed than in most records here. The platform is built against the federal post acute discharge list requirements, which oblige hospitals to give patients quality data and a genuine choice of provider, and the open market model is a direct implementation of that obligation rather than a feature bolted beside it. Led by chief executive Russ Graney. One thing a reader should hold. The company describes an artificial intelligence powered platform, and the identifiable machine learning in it is document intake classification and provider quality analytics. Around that sits a directory, a workflow tool, an authorization tracker and a messaging layer, none of which is inference. No model is described, no performance figure is published for any component, and a dedicated pass located no security page, no external attestation and no published price. This record grades the disclosure available rather than the positioning.

Vitalchat sells ambient virtual care as software rather than as equipment. The platform performs continuous real time analysis of video, audio and sensory data captured in the care setting, identifying trends, predicting risks and flagging anomalies, which it converts into alerts and, by its own description, automated actions supporting the clinical team. Applications cover artificial intelligence assisted virtual sitting for patient safety monitoring, remote procedural support so a clinician can join an operating room or procedure from elsewhere, automated workflows aimed at nursing administrative burden, and virtual engagement letting family remain present during an inpatient stay. The architecture is the differentiator and the reason this record reads differently from the established vendors in this segment. Vitalchat is a cloud native software as a service platform that leverages a hospital's existing infrastructure and states that it eliminates the need for additional hardware. Competitors in inpatient virtual care sell branded endpoints, install them room by room, and carry device fleet management as a core capability. Removing the capital line item entirely is a genuine commercial and operational distinction, and it is also the claim a buyer should probe hardest, because what the software runs on and what it can see depend on what the hospital already has. Deployment is stated at more than 35 hospitals across medical surgical units, intensive care units, operating rooms and post acute facilities. Commercial launch was in 2021. Funding is 6 million dollars in a Series A closed in February 2025, led by Green Harvest Capital Industries. That investor is a private equity firm whose stated specialisms are multifamily housing, hospitality and industrial assets rather than healthcare, which is an unusual profile for a clinical artificial intelligence company and worth noting rather than glossing, since healthcare specialist investors typically bring diligence and customer access that generalist capital does not. Based in Raleigh, North Carolina and led by chief executive Michael Raymer. A reader should understand what this record does not contain. Two dedicated passes located no security page, no external attestation, no health privacy statement, no pricing of any kind, no named customer, no named record system integration and no published performance figure for any model. The company describes what its technology does at the level of capability and publishes almost nothing that would let a buyer verify or evaluate it. That gap, rather than the technology, is the substance of most grades in this record.

Caregility runs the video layer of the hospital and is adding intelligence on top of it. Caregility Cloud, now presented as the Caregility Connected Care Platform, delivers secure two way audio and video into patient rooms across inpatient, ambulatory, post acute and home settings, and applications sit on that layer for specific jobs: iObserver for virtual observation and e sitting, iConsult for virtual consultation, and iCare Coordinator for coordinating bedside clinicians, remote caregivers and AI tools in one place. The scale is larger than any comparable vendor in this index. More than 1,500 hospitals and 75 health systems across multiple continents, over 30,000 connected devices, and more than six million virtual sessions a year. Programmes span virtual nursing, virtual observation, virtual rounding, specialty consults, operating room telehealth and hospital at home. The artificial intelligence is real and is being built rather than inherited. Edge based computer vision runs on the devices, audio sensing detects room duress, and ambient listening and sensor based capabilities are in the platform, with an AI enhanced unlimited patient monitoring capability added to the coordination application in 2026. The 25.1 million dollars raised in September 2025, led by Star Mountain Capital and bringing total outside investment to 92 million, was explicitly earmarked for computer vision, ambient listening and sensor technologies. A Chief Product, Technology and AI Officer holds the portfolio. Integration is the strongest part of the record. Caregility has been listed in Epic Toolbox for Inpatient Virtual Care for two consecutive years including 2026, with named integration paths into MyChart Bedside TV, Epic Monitor, Haiku and Hyperspace, alongside nurse call systems, interactive patient consoles and bedside devices. Ecosystem partners run their own applications on the platform, with a clinical documentation vendor among those named. Connectivity options extend to 5G and satellite for rural and mobile deployment. Compliance disclosure is also stronger than the segment norm. The platform is stated to be HIPAA, GDPR and CCPA compliant and ISO and SOC certified, and a named independent security firm is cited as having verified the HIPAA position. The platform has been recognised as the leading virtual care platform outside the record system vendors by a third party analyst firm in three consecutive years. Based in Wall, New Jersey. One thing a buyer should weigh directly. The footprint here is larger than the closest competitor's and the published evidence is thinner: no peer reviewed study was located, and named customer results are testimonial rather than quantified, where the closest competitor publishes response times, alarm reductions and dollar figures at named institutions. Scale and evidence are different things and this record separates them deliberately.

AvaSure invented virtual sitting and has spent fifteen years turning it into an enterprise platform. A camera in the patient room feeds a remote observer who can speak to the patient through two way audio and summon staff, and computer vision watches alongside that observer, flagging potential falls and other high risk events so attention lands where it is needed. The ratio is the product: a single observer safely covers up to 16 patients, which is what converts one to one sitting into something a hospital can staff. The platform now spans continuous observation, virtual nursing, episodic consults, virtual visits, ambient sensing and an AI agent for virtual care workflows. Hardware comes in fixed and mobile forms, with 1080p cameras carrying 10x optical zoom and 360 degree pan, tilt and zoom, infrared illumination for night vision, and a dual camera variant pairing a wide angle lens for ambient signal capture with a second lens for video consults. Ceiling mounted units are tamper resistant and available in ligature safe configurations for behavioral health. Integration is the part that separates this from a camera system. The virtual visit application launches from within Epic Hyperspace, devices pair with Epic Monitor for virtual observation, and urgent alarms route to nurse call systems in real time over HL7 interfaces, application programming interfaces or middleware. Caregiver acknowledgements then sync back into AvaSure, which closes the loop and makes response measurable rather than assumed. Scale and evidence are both unusual for this index. More than 1,200 hospitals are deployed. A peer reviewed study published in early 2026 evaluated a continuous virtual monitoring programme in a long term acute care hospital across 40 months, reporting sustained safety and financial outcomes. Named customer results include a 38 percent reduction in urgent alarm rates with an 11 second average response time at one health system, and a 16 percent cut in emergency department holding time with a 31 percent improvement in discharge turnaround at an urban safety net hospital. More than 150 customer generated presentations and studies exist, and one health system published 3.2 million dollars in measurable impact. The company began in Grand Rapids, Michigan as a business security integrator and launched the TeleSitter line in 2009, adding a team of registered nurses who run the clinical education programme that accompanies the technology. Importantly for membership here, AvaSure sells the platform and the hospital staffs the observers, which is what distinguishes it from managed monitoring services that supply observers from their own centre. One disclosure worth knowing before procurement. AvaSure publishes no rate card, but a United States Department of Veterans Affairs solicitation sets out the commercial structure in the open: software licensed per hardware device on an annual term at a named tier, with support tiered separately, and hardware, clinical services, monitor stations and installation carried as distinct line items. A federal variant of the hardware carries validated cryptography.

Operating room block time optimisation built around a machine learning prediction. The platform, ARDEN, forecasts which allocated surgical block time is likely to go unused and reallocates it according to the facility's financial objectives, clinical priorities and individual surgeon preferences, making recovered time available to surgeons looking for capacity. Modules are separately installable. Buyers are hospitals and ambulatory surgery centres. Founded by Michael Burke, chief executive, and Keyton Weissinger. Based in the Atlanta area, with sources giving both Atlanta and Alpharetta, and disagreeing on founding year between 2019 and 2021. The design combines machine learning with behavioural economics, which is an unusual pairing and the more interesting half of the proposition. Predicting an unused block is a modelling problem; persuading a surgeon to release time they have been allocated and may want to keep is an incentive problem, and the company treats both as part of the product rather than assuming the prediction is sufficient. This record sits deliberately alongside the two perioperative vendors built immediately before it, because the three together show the range in one narrow lane. LiveData has thirty five years of workflow software and a conversational query layer three months old, so its intelligence is peripheral. Apella raised 101 million dollars to put computer vision in the room, so its intelligence is the entire product. Copient is a six person company whose intelligence is also the entire product. Scale and centrality are independent, and a buyer comparing the lane should see that. Scale and viability are the material risk on this record. Funding is 3.2 million dollars raised in a single Series A in January 2022 led by Atlanta Ventures with First Trust Capital Partners and Atlanta Seed Company, with no subsequent round located more than four years later. Headcount was reported at six in July 2024 with no more recent figure found. A hospital signing a multi year agreement for a system that reallocates surgeon block time should weigh continuity alongside capability. Disclosure is minimal. A dedicated pass located no named customer, no outcome figure, no security certification, no trust page, no integration specification and no pricing information. Published material consists of product description and a marketing blog. The grades below reflect that and are a finding about what a buyer can verify rather than a judgement about whether the model works.

Perioperative workflow and surgical capacity software, independent and operating from Cambridge, Massachusetts since 1991. Annual revenue is estimated by a third party at roughly 7 million dollars, making this one of the smallest records in the index by revenue and one of the oldest by tenure. The product is the PeriOp Manager suite, a set of coordinated modules rather than a single application: PeriOp Planner for surgical scheduling, Patient Flow for check in and check out, PreOp Board, OR-Dashboard with Active Time Out, OR-Schedule Board, Family Waiting Board, Procedure Suite Manager, PeriOp Mobile Messenger and PeriOp Manager Analytics, with LiveData Insights as the analytics cloud above them. OR-Dashboard blends data from the electronic record, anaesthesia systems and physiological monitoring devices into a live view of the case, and staff record milestones and complete safety checklists through a wireless handheld device. That capture method is the reason this record is worth reading alongside Apella. Both companies produce the same underlying dataset, surgical case events timed to the minute, and they obtain it in opposite ways: one by having a member of staff press a button, the other by computer vision inferring the event autonomously. The trade is explicit rather than theoretical. The manual route costs staff attention and produces a record a human authored; the automated route costs nothing at the point of care and produces a record no human reviewed. A buyer choosing between them is choosing which of those they prefer, and the index should let them see it. The artificial intelligence is new and narrow. LiveData Insights AI Advisor launched 21 May 2026 as a conversational layer allowing leaders to ask plain language questions about block utilisation, case volume, late starts and turnover time, with answers stated to be grounded in the health system's own data rather than generic benchmarks. It works with any electronic record, requires no proprietary data pipeline, and runs inside the existing analytics cloud with role based access. A chief product officer was appointed in 2026 specifically to accelerate artificial intelligence work, which places the company at the beginning of that transition rather than partway through it. One credential stands out and has nothing to do with artificial intelligence. OR-Dashboard with Active Time Out has been designated a Leading Practice by the hospital accreditation body, which is a patient safety recognition from the organisation that inspects hospitals rather than a marketing award, and is the only credential of that character encountered in this sweep. The company was also named among 25 Forbes Small Giants in 2019. Disclosure limitation: a dedicated pass located no security certification, trust page, pricing information or named customer.

Ambient artificial intelligence and computer vision for the operating room. Sensors installed in the room observe surgical activity, machine learning models automatically identify up to fourteen distinct case events, and the resulting structured data is written autonomously back into the electronic record and fed into scheduling, utilisation and turnover analytics. Founded 2020 by David Schummers, chief executive, and Cameron Marlow, chief technology officer. Headquartered in San Francisco, with some sources giving Oakland. The rationale is concentration of value rather than breadth. The company states that up to 60 percent of a health system's revenue and 40 percent of its costs sit in the operating room, which makes perioperative capacity the highest leverage target in hospital operations. A later product, Horizon, forecasts case duration and utilisation to optimise scheduling before the day begins rather than reacting during it. Funding totals 101 million dollars: a 21 million dollar Series A in December 2021 led by Casdin Capital, and an 80 million dollar Series B of equity and venture debt announced 8 January 2026 led by HighlandX, with returning investors Vensana Capital, Casdin Capital, PFM Health Sciences, Upside Partnership and Operator Partners, and new investors K2 HealthVentures, OpAmp Capital and Houston Methodist. The president of the Johns Hopkins Health System joined the board. The flagship deployment is Houston Methodist, a nine hospital system that ran an initial 36 room pilot and has since scaled to more than 200 operating rooms enterprise wide, with its executive vice president and chief innovation officer quoted on the result. That reference carries a disclosed conflict this record records plainly: Houston Methodist is also an investor in the Series B, and the quoted executive appears among the company's individual investors. The evidence is real and the commercial relationship runs both ways. The headline outcome claim is an average 5 percent increase in surgical volume across customers, vendor stated with no methodology or study attached. Two characteristics distinguish this record from everything else in the lane and drive several grades. The system writes machine generated observations autonomously into the legal medical record, which is a different act from advising a human. And the data it collects is continuous video of surgical procedures, capturing patients under anaesthesia and the staff around them. Neither is addressed in any published material located, and both are recorded on the relevant axes. Disclosure limitation: a dedicated pass located no security certification, trust page, privacy posture, integration specification or pricing information. The trust axes are graded conservatively on that basis and should be revisited.

Enterprise patient flow, electronic patient record and clinical decision support software, and the only vendor in this index whose business sits almost entirely outside the United States. Listed on the Australian Securities Exchange, led by managing director and chief executive Kate Quirke. All figures below are Australian dollars. The platform is Miya Precision, positioned as modernising legacy health systems by standardising data across complex environments and delivering real time clinical decision support on top of it. Coverage spans patient flow and bed management, command centre operations, emergency department workflow, care coordination, virtual care and, increasingly, full electronic patient record deployments. In June 2026 the company completed the acquisition of the Kyra flow products from Telstra Health, adding 33 customers of which 31 were new and consolidating its position in the Australian patient flow market. Scale is documented rather than claimed, because listing obliges it. The platform runs across more than 400 hospitals globally, supporting more than 50,000 beds and 130,000 active users. Customers include more than 40 National Health Service trusts in the United Kingdom, healthcare providers in every Australian state and all four regions of New Zealand Health, with stated expansion interest in Canada and the Middle East. Named customers include University Hospitals Sussex, Harrogate, Northumbria, Dartford and Gravesham, Hywel Dda and Western Health, the last of which renewed for a fifth time across twenty years. Financial disclosure is unmatched in this index. Revenue for the year ended 30 June 2026 was 51.6 million dollars, up 27 percent, split 63 percent United Kingdom and 37 percent Australia and New Zealand, with annual recurring revenue of 38.3 million dollars up 34 percent and a record 78.5 million dollars of new and renewal total contract value. Individual contracts are disclosed: the May 2026 University Hospitals Sussex electronic patient record agreement runs seven years at roughly 35 million dollars, extendable to roughly 49 million dollars over ten. The artificial intelligence is a layer rather than the product. The company describes a growing suite of generative capabilities inside Miya Precision covering clinical documentation, summarisation and problem detection, and management frames the platform as one that standardises data and helps deploy algorithms safely in regulated healthcare settings. That framing is close to the infrastructure position this index rejects elsewhere, and the record sits inside the boundary because the company builds its own decision support and generative capability rather than solely carrying other parties' models. The centrality grade reflects the balance. Two record keeping notes. The specific city of headquarters was not confirmed in this pass, and neither was the founding year, so both are omitted rather than guessed. And two axes in this framework, the federal privacy posture and the device regulator status, assume a United States vendor and map poorly here; both are graded against the equivalent obligation in the company's actual markets and the reasoning is recorded on each.

Patient flow and capacity management for hospitals and health systems, and the incumbent against which LeanTaaS and Qventus are usually evaluated. Headquartered in Pittsburgh, operating for more than three decades, with a reported 369 employees and a stated global footprint of more than 200,000 managed beds representing millions of patient stays annually across North America and Europe. The product is the Operations IQ Platform, rebranded in October 2024 as the company completed a move from installed software to a hosted model. Capacity IQ handles bed management, discharge efficiency, turnover and emergency department boarding. Workflow IQ covers perioperative settings. Transfer IQ manages patient transfers within and between facilities. Referral IQ connects owned and affiliated referring providers. Data IQ delivers enterprise analytics. Underneath sits three decades of workflow automation, transport dispatch and real time location technology, which the company combined with patient flow software to create a real time capacity platform. The artificial intelligence is recent and is one module among several. Decision IQ launched on 20 November 2025 as what the company describes as the first artificial intelligence driven solution for managing patient flow at scale, replacing retrospective reporting with forward looking system wide visibility so teams can anticipate throughput constraints before they bite. University of Louisville Health is the named early adopter, expanding a longstanding transfer operations relationship. The company's own framing pairs more than thirty years of operational expertise with advanced artificial intelligence, which is an accurate description of the balance and is the reason the centrality grade on this record sits low. Membership was decided on the centrality grade rather than the reject filter, following the Aetion precedent. This is a healthcare only technology company rather than a horizontal vendor and it is not a services business, so neither of those filters applies. What is true is that most of the platform would function without a model, and that is recorded on the axis built for it rather than treated as disqualifying. Ownership note requiring verification before quotation: one vendor database records the company as acquired by an entity named Aionex, and no confirming source was located. The brand plainly survives under its own name regardless, carrying its own domain, its own current copyright, its own product line and a November 2025 product launch in its own name, so the acquired vendor ruling is satisfied either way. The gap across this record is disclosure rather than capability. A dedicated pass located no security certification, trust page, privacy posture, pricing information, integration specification or published outcome figure for the artificial intelligence product. For a vendor of this tenure and installed base, that is a striking amount of nothing.

DeepHealth is the umbrella brand for RadNet's Digital Health segment and the entity that contracts RadNet's clinical AI and imaging informatics software to third party providers. It is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), headquartered in Somerville, Massachusetts, and the brand was launched in November 2023 to consolidate a sequence of acquisitions. Those absorbed brands are named here because this index has no aliases field and they are otherwise liable to be rebuilt as separate vendors: eRAD (radiology information systems and picture archiving, now rebranded into Diagnostic Suite and Operations Suite), the original DeepHealth breast AI company, Aidence (lung), Kheiron (breast), Quantib (prostate and brain), See-Mode (thyroid and vascular ultrasound), iCAD (acquired July 2025 for a reported 103 million dollars, bringing the ProFound Breast Health Suite covering detection, density, risk and breast arterial calcification), CIMAR UK (cloud image management, acquired November 2025) and Gleamer SAS (Paris, acquired 2 March 2026, all cash, up to 230 million euros comprising about 215 million at closing plus a 15 million contingent milestone, bringing musculoskeletal, chest and neuro radiograph AI including BoneView). Gleamer retains its own record at [[gleamer]] because it still carries a distinct brand, product line and customer base. The portfolio is anchored on DeepHealth OS, a cloud native operating system, and divides into enterprise imaging (Diagnostic Suite, a picture archiving replacement; Operations Suite, covering scheduling, registration, billing and analytics; TechLive for remote multimodality scanning; Reporting Pro) and population health clinical AI (Breast Suite, including SmartMammo Dx, also known as Saige-Dx, with density, risk and breast ultrasound modules, plus Chest, Prostate, Neuro and Thyroid suites). Company published scale, combined with Gleamer: more than 2,700 customer contracts across more than 50 countries, 26 FDA cleared and 22 CE marked devices, more than 300 screening sites and more than 10 million mammograms a year. Third party traction is disclosed separately, with more than 16 million dollars of total contract value in new business signed in the first quarter of 2026, and named external customers including ONRAD, which serves more than 120 hospitals and radiology groups, and Wichita Radiological Group. The evidence base is led by the ASSURE study, published in Nature Health in November 2025 (Louis et al., doi 10.1038/s44360-025-00001-0), a prospective analysis of 579,583 women across more than 100 community imaging sites in four states. It compared an AI driven workflow (208,891 examinations) against the prior standard of care (370,692) and reported a 21.6 percent increase in cancer detection rate, 5.6 against 4.6 per thousand, with no significant variation across socio demographic or breast density subgroups and a 22.7 percent gain in women with dense breasts. Co authors include external academic investigators alongside RadNet's chief science officer. The comparison is against historical control rather than randomised, and the sites are substantially RadNet's own, which is addressed on the evidence axis.

care.ai turns patient rooms into sensed environments for virtual nursing and virtual monitoring, using camera based sensors with graphics processing units on the unit itself, so computer vision runs at the bedside rather than in a distant cloud. From a single virtual command centre, remote nurses or sitters support the bedside team, and Stryker states that one remote nurse can monitor, assess and support up to ten patients at once using the real time data the ambient system produces. The company was based in Orlando, Florida and was acquired by Stryker in 2024 for an undisclosed sum. It no longer trades independently, and this record is scoped to the care.ai product line, which Stryker continues to market under that name. What has changed since is the context around it. In March 2026 Stryker launched its SmartHospital Platform, run by a newly formed Smart Care business, which brings care.ai's ambient intelligence and virtual care workflows together with more than 85 Stryker products on one interface. Those include the ProCuity bed, the Vocera hands free communication devices and Sync Badge that Stryker acquired for close to 3 billion dollars in 2022, and the Engage middleware engine that filters and prioritises alarms. Vocera alone integrates with more than 150 clinical and operational systems including record systems, nurse call, ventilators and physiological monitors. So a hospital evaluating this is no longer evaluating an ambient intelligence vendor. It is evaluating one module of a medical device manufacturer's connected ecosystem, sold modularly but designed to be adopted together, and the more of that ecosystem a hospital already owns the more the ambient layer is worth to it. Anyone searching for care.ai or Vocera is looking at Stryker.

Cynerio secures the connected devices inside hospitals, and it was built for healthcare from the outset rather than adapted to it. Founded in 2017 and based in New York, with Samsung NEXT among its investors, it was acquired by the asset management company Axonius in July 2025 for a reported figure above 100 million dollars and now operates inside that platform. Anyone searching for Cynerio is looking at an Axonius business. The platform has three parts. Network detection and response for healthcare uses deep packet inspection and behavioural anomaly detection to identify threats on clinical networks in real time. Medical device security discovers connected devices automatically, assesses their risk and offers mitigation through micro segmentation and patching. Complete asset visibility maintains a single inventory across information technology, operational technology and connected medical devices with compliance reporting. Two things distinguish it from its peers. In 2021 it released an attack detection and response module that goes beyond inventory to containment, letting a hospital quarantine a device showing malicious behaviour immediately while deferring full remediation until the device is not in use, so that a patient connected to it is not affected. And its patient data security module is data centric rather than device centric: it identifies where electronic protected health information is exposed across clinical systems, maps data flows between devices and external parties, and monitors access patterns. The company co produced research with the Ponemon Institute, surveying leaders at 517 United States health systems, which found that 71 percent rated connected device risk as high or very high while only 21 percent described their protections as mature, and reported that organisations suffering cyberattacks saw increases in bed days, mortality, affected procedures, transfers and complications. That work is now cited in the professional literature on medical device security. It integrates with Microsoft Sentinel, belongs to the Microsoft Intelligent Security Association, and sells through managed security providers as well as directly.

IntelyCare matches nurses and nursing assistants to open shifts, and the machine learning does two jobs rather than one: it optimises the match and it optimises the price. Facilities pay a flat rate for the platform, and the wage offered for a given shift is set according to how easy or hard that shift is to fill. Founded in 2016 near Boston by David Coppins, Ike Nnah and Chris Caulfield, and based in Quincy, Massachusetts, it has raised roughly 174 million dollars. A 45 million dollar Series B in 2020 drew Endeavour Vision, Kaiser Permanente Ventures and Generator Ventures; a 115 million dollar Series C in April 2022 led by Janus Henderson took the valuation above 1.1 billion dollars. Coppins moved from chief executive to executive chairman, and Matthew Levesque now leads the company. In January 2026 it acquired CareRev, the on demand workforce platform for acute care, with both brands continuing to operate. That took the company from its post acute origins into hospitals and produced a combined offering spanning permanent staff, internal resource pools and contingent labour in one system. Anyone searching for CareRev is looking at this group. The employment model is a deliberate counter position in a market of gig platforms. Nurses on the platform, called IntelyPros, are employed as W2 workers with health, retirement and education benefits, which the company frames as giving the flexibility of gig work without the instability of traditional agency work. The technology learns from every interaction, taking in nurse and facility preferences and a two way rating system to improve matching over time, and the company states it creates shifts before facilities recognise their own need. Hours are validated by geofencing when a nurse checks in and out through the mobile application. Reported performance is a fill rate around three times the industry average, which the company describes as the highest in the market.

Mednition sells KATE, a clinical artificial intelligence platform that works at the emergency department triage desk rather than on the ward. It was founded in 2014, is based in Burlingame, California, and is led by chief executive Steven Reilly. KATE reads the structured intake data a triage nurse enters together with the free text of their notes, compares it against patterns from millions of prior visits, and recommends an acuity level in real time. The company is explicit that it supports rather than replaces the nurse's judgement, adds no new screens and requires no workflow change, which matters because triage is the most time pressured decision point in the hospital. The sepsis model is the flagship. KATE Sepsis received Breakthrough Device Designation from the Food and Drug Administration in November 2023 for detecting sepsis at triage, before any laboratory result exists. It has not been cleared: the designation expedites review rather than authorising marketing, and no clearance was located nearly three years later. Performance is published in preprints with named authors rather than only in marketing copy. An early model reported an area under the curve of 94 percent for sepsis detection at triage. A later model reported an area under the curve of 99 percent with 95 percent sensitivity and 96 percent specificity, on a retrospective cohort of 540,884 patients containing 14,676 positive sepsis cases across 16 hospital sites, using the current academic sepsis definition. Against standard screening protocols the company reports sensitivity improvements of 74 percent for sepsis, 80 percent for severe sepsis and 118 percent for septic shock. The company names the failure mode its category is known for rather than avoiding it, stating that the challenge has been achieving high sensitivity without a collapse in specificity and the false positive rates and alert fatigue that follow. Adventist Health has adopted KATE systemwide, and named sites include Shady Grove, White Oak, Fort Washington and Glendale. A separate paediatric safety product covers the same triage moment. KATE was named best in show in the capacity crisis category at the 2025 HIMSS conference.

Cerebriu is a Copenhagen company founded in 2018 whose Apollo suite intervenes in a brain MRI examination while it is still happening, rather than analysing the images afterwards. Its founders are Akshay Pai, Robert Lauritzen, who is chief executive, Erik Dam, Mads Nielsen and Martin Lillholm. The suite has three parts. Smart Protocol analyses an abbreviated opening set of images and suggests which sequences should be acquired next, so the protocol adapts to what has already been seen while the patient is still on the table. Smart Alert detects critical findings during the examination itself, naming infarcts, intracranial haemorrhage and tumours, so a scan can be escalated before the patient leaves. Smart Reading prioritises high risk studies in the reporting queue. Regulatory position is European rather than American. Apollo is CE marked under both the older medical device directive and the current regulation, while clearance from the Food and Drug Administration is described as pending and the United States status is stated as for investigation only. In 2025 the company secured CE marking for Apollo Smart Protocol as a product embedded inside a Siemens Healthineers MRI system, which it describes as the first clearance anywhere for clinical artificial intelligence embedded in a scanner from a major manufacturer. A validation study published in the European Journal of Radiology in September 2023 reported roughly 89 percent sensitivity and 90 percent specificity for ischaemic lesions across 800 patient scans. Deployments span hospitals in Denmark, the United States, Norway, India, Israel and Brazil. Funding totals about 26.8 million euros, comprising a 17.4 million euro Series A in 2024 led by North Ventures with EIFO, Denmark's export and investment fund, and Sagitta Ventures, followed by 9.4 million euros in 2025. The company also distributes through two independent radiology artificial intelligence platforms, CARPL and deepc, alongside its manufacturer route.

LeanTaaS sells capacity optimisation software to hospitals under the iQueue brand, forecasting demand and rescheduling scarce assets so that fewer of them sit idle. The name is short for Lean Transformation as a Service, and the company was founded in 2010 in Santa Clara, California by Mohan Giridharadas, previously a senior partner at McKinsey who led its lean operations practice in North America and Asia Pacific. The products address three assets that constrain hospital throughput. iQueue for Operating Rooms reallocates surgical block time, a problem the company states it first solved at UCHealth. iQueue for Infusion Centers schedules chemotherapy chairs, which began as a partnership with Stanford Health Care. iQueue for Inpatient Flow manages bed capacity, a capability strengthened by the acquisition of Hospital IQ. In 2024 the company added iQueue Autopilot, described as the first generative artificial intelligence product for hospital operations. The underlying mechanism is described as patented optimisation algorithms combining lean principles, predictive and prescriptive analytics and simulation. The scale is the largest of any operations vendor in this index. Nearly 200 health systems across more than 1,200 hospitals use one or more products, covering more than 5,600 operating rooms, 14,500 infusion chairs and 23,000 inpatient beds. Named customers include Stanford Health Care, UCHealth, UCSF, NewYork Presbyterian and Intermountain Health. A partnership with Siemens Healthineers was announced to optimise operational performance. KLAS named it Best in KLAS for Capacity Optimization Management in 2026 with a score of 95.6 out of 100, the highest in its category, having also won the category the previous year. The company has raised roughly 250 million dollars across ten rounds from investors including Insight Partners and Goldman Sachs, reports annual contract value approaching 150 million dollars and 170 percent revenue growth over three years, employs around 400 people, and has taken private equity investment from Bain Capital.

Artisight sells a smart hospital platform that turns a patient room into a sensed environment. A multi sensor network of cameras, microphones and positioning hardware runs computer vision and speech models on graphics processing units installed on site, and the system continuously observes the room and responds to what it sees and hears. The capability list spans several jobs the index usually treats separately: virtual nursing, virtual observation in place of an in person sitter, fall prevention, ambient documentation of room activity, two way audio and video for tele consultation, vital sign monitoring, indoor positioning, and surgical case length prediction in the operating room. The company describes itself as an ambient intelligence platform deployed across clinics, patient rooms and operating rooms rather than as a point solution. It was founded in 2015 by Andrew Gostine, a physician, and is based in Chicago. It raised a 42 million dollar Series B in January 2024 that was oversubscribed and included NVIDIA among the investors, followed by a further 40 million dollars reported in August 2025, at which point the platform was described as in use at 417 hospitals including Northwestern Medicine, WellSpan and the Guthrie Clinic. A notable feature of the capital structure is that many client hospitals are also investors. Northwestern Medicine is cited as reporting an 89 percent reduction in falls, a 52 percent reduction in nursing overtime and a 76 percent reduction in nursing turnover. In 2024 the chief executive stated that publication of these results in the peer reviewed literature was anticipated. No such publication was located in this pass.

TransformativeMed, based in Seattle under chief executive David Stone, sells the CORES Platform, a set of clinician facing workspaces embedded directly inside the electronic health record rather than sitting alongside it. Built originally on the Cerner MPages extension toolkit and now positioned around Oracle Health Millennium, with Epic deployments as well, it reorganises record data into specialty specific views: patient lists carrying each patient's current issues, rounding preparation, handoff, discharge readiness, task synchronisation across the care team, alert routing through Core Notify, secure messaging, and disease specific modules including one for diabetes. A mobile companion both reads from and writes back to the record. Its own founding description of the method is a proprietary knowledge engineering process, which is configuration and clinical content design rather than a learned model, and the artificial intelligence in the current product arrives largely through a September 2025 partnership with Vantiq, whose real time platform supplies the agentic capability. The company was named 2026 Best in KLAS winner for clinician digital workflow, and has run at University of Washington Medicine, University of Alabama at Birmingham, University of Tennessee Medical Center, a Veterans Affairs division and King Faisal Specialist Hospital.

TheraDoc is one of the two incumbent clinical surveillance platforms in American hospitals, monitoring live feeds of laboratory, microbiology, pharmacy and admission data to raise alerts for infection prevention, antimicrobial stewardship, pharmacy surveillance and anticoagulation management, and to produce mandatory infection reporting. It was founded in Salt Lake City in 1999, sold to Hospira, and acquired by Premier in 2014 for 117 million dollars in cash, and is now marketed as Premier's Clinical Surveillance powered by TheraDoc. Its mechanism is a rules engine rather than a model: pharmacists and infection preventionists author their own alert logic, and the system evaluates those written queries continuously against incoming data. Premier makes no artificial intelligence claim for the product on its own pages, which is more accurate than what its principal competitor publishes. The one genuine model inside the product is licensed rather than built, since Premier's own material states that the integrated precision vancomycin dosing tool in TheraDoc comes from InsightRX. Two ownership facts matter for procurement. Premier completed a 2.6 billion dollar take private by Patient Square Capital, having reported an eleven percent revenue decline in fiscal 2025 and having explored strategic alternatives since 2023. And Premier separately owns Stanson Health, so a single supplier now sits behind both this surveillance platform and a point of care decision support product.

VigiLanz is the other incumbent clinical surveillance platform in American hospitals and the direct competitor to TheraDoc. Founded in Minneapolis in 2001 by David Goldsteen and acquired by Inovalon in February 2024, it ingests near real time data from any electronic health record, including admission feeds, medication administration records, laboratory results, microbiology and medication history, across acute, post acute and ambulatory settings, and converts it into alerts for pharmacy surveillance, infection prevention, antimicrobial stewardship, quality improvement and patient safety event reporting. The mechanism is configurable rules, and the company's own product page describes it in a phrase worth quoting because it captures the entire problem this index exists to address: flexible, rule based AI. Independent product listings describe the same engine plainly as configurable and rule based. Alerts surface directly inside the electronic health record for faster acknowledgement, and the platform supports intravenous to oral conversion review, antibiogram trending and transitions of care. As with its competitor, the genuine model reaching clinicians through the product is licensed from elsewhere: Inovalon announced a collaboration in October 2025 bringing DoseMeRx precision dosing into these pharmacy surveillance workflows. The company cites eight consecutive years as the leading pharmacy surveillance solution in one analyst firm's rankings.